Akeso (HKEX: 9926) announced that all approved indications for its five self-developed drugs were secured in China’s updated National Reimbursement Drug List (NRDL) effective Jan. 1, 2026, materially expanding market access. Key wins include ivonescimab (PD‑1/VEGF bispecific) with a Phase III result showing a 49% reduction in progression/death versus pembrolizumab for first‑line PD‑L1+ NSCLC, new first‑line indications for cadonilimab in gastric and cervical cancer, and NRDL inclusion for penpulimab, ebdarokimab (psoriasis) and ebronucimab (both hypercholesterolemia indications). The broad NRDL coverage should meaningfully lower patient cost, accelerate adoption and commercialization in China and is likely to be a material positive for Akeso’s revenue trajectory and investor sentiment.
Market structure: NRDL inclusion is a demand-side shock that materially increases addressable patient volume for Akeso (9926.HK) across five marketed assets; expect hospital uptake to rise quickly in Tier 1–3 hospitals with a 3–9 month lag as provincial procurement and formularies update. Winners include Akeso (9926.HK) and other domestic innovators with NRDL coverage; losers are foreign incumbents in China (e.g., MRK for PD‑1, AMGN/SAN for PCSK9) whose share and pricing power in China will be pressured. Net effect: unit price per treatment likely falls via negotiated reimbursement but total revenues should rise — think +15–35% revenue for covered indications in year 1, with margin compression of 5–12 percentage points depending on gross-to-net dynamics.
Risk assessment: Tail risks include aggressive follow‑on NRDL price cuts in subsequent rounds, supply chain/manufacturing shortfalls limiting hospital deliveries, and patent/legal challenges; each could erase >30% of upside within 6–12 months. Immediate risks (days–weeks) are muted; meaningful volatility will come at quarterly sales prints and provincial procurement announcements (30–90 days) and over 6–18 months as volumes scale. Hidden dependencies: provincial reimbursement implementation, hospital budget cycles, and physician adoption drive realized uptake — absence of any produces a pronounced revenue miss. Key catalysts: Jan–Mar 2026 sales data, provincial inclusion lists, and any global regulatory news (FDA filings/approvals) that expand ex‑China markets.
Trade implications: Direct play = establish a 2–3% long position in Akeso (9926.HK) for 6–18 months to capture re‑rating from NRDL-driven volume; use 6–12 month OTM call spreads or long equity with a 15–20% protective put if options/liquidity allow. Pair trade = long 9926.HK vs short AMGN or MRK exposure to China PCSK9/PD‑1 sales (size 1–1.5%) for 3–12 months to capture share shift; rebalance on provincial procurement releases. Sector rotation: overweight China-listed biotech and hospital suppliers that benefit from higher volumes; reduce exposure to imported oncology/biologics names with high China revenue concentration where price erosion >20% risk.
Contrarian angles: Consensus celebrates volume growth but underestimates margin erosion from NRDL pricing and competitive entry — market may be underpricing the downside if Akeso must cut ASPs by >25% to secure volume. Historical parallels: prior NRDL waves (2019–2021) produced 2–3x volume growth but often compressed margins and forced faster geographic expansion; if Akeso fails to scale manufacturing, upside evaporates. Unintended consequences: faster adoption could invite stricter price renegotiations next cycle, capping sustainable ASPs and limiting long‑term FCF; size positions accordingly and force‑rank exposure by visibility of provincial rollout.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
